Altogether, these data indicate that anti-PD-1 therapy induces a de novo immune response, stimulated by the presence of metastatic cells, and composed of different T cell subtypes, which may trigger the development of vitiligo and response against a metastatic tumor [49]. The gene discussed is PDCD1; the disease is vitiligo.